Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.
about
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma.
P2860
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Optimizing current and emergin ...... a guide for the hematologist.
@ast
Optimizing current and emergin ...... a guide for the hematologist.
@en
Optimizing current and emergin ...... a guide for the hematologist.
@nl
type
label
Optimizing current and emergin ...... a guide for the hematologist.
@ast
Optimizing current and emergin ...... a guide for the hematologist.
@en
Optimizing current and emergin ...... a guide for the hematologist.
@nl
prefLabel
Optimizing current and emergin ...... a guide for the hematologist.
@ast
Optimizing current and emergin ...... a guide for the hematologist.
@en
Optimizing current and emergin ...... a guide for the hematologist.
@nl
P2093
P2860
P356
P1476
Optimizing current and emergin ...... a guide for the hematologist.
@en
P2093
Evan Rosenbaum
Rachael A Safyan
Shahzad Raza
Suzanne Lentzsch
P2860
P356
10.1177/2040620716680548
P577
2016-12-09T00:00:00Z